M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug PharmaphorumServier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.Rare DiseaseRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaphorum Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten. Rare Disease Read full story Post navigation Previous: ASCO: Summit reached with China lung data but new climb begins to prove global benefitNext: CordenPharma inks AmbioPharm buyout to continue peptide production expansion Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
